AUTHOR=Mohammed Omima S. , Attia Hany G. , Mohamed Bassim M. S. A. , Elbaset Marawan A. , Fayed Hany M. 

TITLE=Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches

JOURNAL=Journal of Pharmacy & Pharmaceutical Sciences

VOLUME=Volume 26 - 2023

YEAR=2023

URL=https://www.frontierspartnerships.org/journals/journal-of-pharmacy-pharmaceutical-sciences/articles/10.3389/jpps.2023.11808

DOI=10.3389/jpps.2023.11808

ISSN=1482-1826

ABSTRACT=Long-term liver injuries lead to hepatic fibrosis, often progressing into cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. There is currently no effective therapy available for liver fibrosis. Many chronic injuries result in hepatic fibrosis, which frequently develops tointo cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. Currently, effective treatment of liver fibrosis is still lacking. Thus, continuous investigations for anti-fibrotic therapy are ongoing. The main theme of anti-fibrotic investigation during the recentrecent years is the rationale-based selection of treatment molecules according to the current understanding of the pathology of liver the diseasefibrosis. The research efforts are mainly toward repurposing current FDA-approvedFDA approved drugs targetingthat can target aetiologicaletiological molecular factors involved in developingthe development of the liver fibrosis. In parallel, investigationinvestigations also focusare also focusing on experimental small molecules with evidence to hinder of or reverse the fibrosis. Natural compounds, immunological, and genetic approaches are also have showned significant encouraging effects . This review summarizes the efficacy and safety of current under-investigation antifibrosis medications targeting various molecular targets, as well as the properties of antifibrosis medications, mainly in phase II and III clinical trials.